Table 1

Baseline demographic characteristics of study population per group.

M (SD)Overall sample
(n=88)
Intervention group
(n=44)
Control group
(n=44)
Lost to follow-up (n=8)
Age56.6 (15.2)57.0 (14.2)56.3 (16.2)53.5 (12.11)
Female N (%)53.0 (60.2)27.0 (61.4)26.0 (59.1)6 (75)
BMI29.5 (6.1)28.9 (5.9)30.1 (6.3)32.7 (4.3)
Length of diagnosis24.0 (17.5)25.2 (17.2)22.8 (17.8)30 (18.9)
FEV1 2.5 (0.8)2.6 (0.8)2.5 (0.8)2.40 (0.47)
% predicted FEV1 92.3 (16.0)94.8 (16.0)89.8 (15.8)92.0 (12.9)
FEV1/FVC76.6 (8.5)77.1 (8.0)76.1 (9.0)74.9 (4.1)
Peak flow421.2 (104.7)421.3 (108.3)421.1 (102.3)420.6 (83.8)
Ethnicity
 White N (%)84 (95.5)42 (95.5)42 (95.5)7 (87.5)
 Other N (%)4 (4.5)2 (4.5)2 (4.5)1 (12.5)
Smoking status
 Current N (%)9 (10.2)7 (15.9)2 (4.5)2 (25.0)
 Former N (%)29 (33.0)13 (29.5)16 (36.3)3 (37.5)
 Never N (%)50 (56.8)24 (54.5)26 (59.1)3 (37.5)
Age left education18.5 (5.3)19.4 (7.0)* 17.7 (2.7)20.4 (8.2)
 16 or under N (%)40 (46.5)18 (42.9)22 (50.0)4 (50.0)
 17–18 n (%)22 (25.6)9 (21.4)13 (29.5)1 (12.5)
 Above 18 (%)24 (27.9)15 (35.7)9 (20.5)3 (37.5)
Index of Multiple Deprivation
Mean Rank (median decile)
17 192 (5.5)17 231 (6.5)17 212 (5)4505.5 (1.5)
AQLQ4.81 (1.01)4.85 (0.94)4.78 (1.09)4.26 (0.55)
ACQ1.45 (0.80)1.35 (0.66)1.56 (0.91)1.52 (0.73)
HADS-A6.60 (4.47)6.57 (3.87)6.64 (5.04)8.63 (3.9)
HADS-D3.89 (3.57)3.39 (3.07)4.39 (3.99)4.75 (4.4)
EQ-5D-5L0.83 (0.19)0.86 (0.15)0.81 (0.22)4 (50.0)
EQ-5D-VAS71.5 (18.2)70.0 (19.3)73.0 (17.2)1 (12.5)
ICECAP-A0.87 (0.18)0.89 (0.12)0.88 (0.16)3 (37.5)
PEI2.52 (1.23)2.44 (1.09)2.60 (1.37)2.73 (1.0)
MARS-A4.70 (1.05)4.80 (0.90)4.60 (1.20)4.3 (0.8)
  • *Percentages are reported from 42 participants as 2 participants in the intervention group did not complete these data.

  • ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; EQ-5D-5L, EuroQol Five Dimensional Quality of Life; EQ-5D-VAS, EuroQol-5D Visual Analogue Scale; FEV1, forced expiratory volume; FVC, forced vital capacity; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; ICECAP-A, Icepop Capability measure for Adults; MARS-A, Medication Adherence Rating Scale for Asthma; PEI, patient enablement instrument.